ICER Review Of NSCLC Drugs To Include Roche’s Pending Indication For Tecentriq

Institute for Clinical and Economic Review aims to complete cost effectiveness analysis of non-small lung cancer drugs in time for supplemental approval of the newest PD-L1 inhibitor in the space.